193 related articles for article (PubMed ID: 27012201)
21. Ring finger protein 19A is overexpressed in non-small cell lung cancer and mediates p53 ubiquitin-degradation to promote cancer growth.
Cheng Y; Hu Y; Wang H; Zhao Z; Jiang X; Zhang Y; Zhang J; Tong Y; Qiu X
J Cell Mol Med; 2021 Aug; 25(16):7796-7808. PubMed ID: 34184814
[TBL] [Abstract][Full Text] [Related]
22. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis.
Li Y; Zhou Z; Chen C
Cell Death Differ; 2008 Dec; 15(12):1941-51. PubMed ID: 18806757
[TBL] [Abstract][Full Text] [Related]
23. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
Yan D; Zheng X; Tu L; Jia J; Li Q; Cheng L; Wang X
Mol Med Rep; 2015 Jan; 11(1):295-302. PubMed ID: 25352209
[TBL] [Abstract][Full Text] [Related]
25. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.
Ning Y; Hui N; Qing B; Zhuo Y; Sun W; Du Y; Liu S; Liu K; Zhou J
Cell Death Dis; 2019 May; 10(6):414. PubMed ID: 31138778
[TBL] [Abstract][Full Text] [Related]
26. TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies.
Wang J; Liang X; Yu T; Xu YL; Xu LH; Zhang XJ; Ma J; Wang YR; He SL
Cell Biol Int; 2018 Nov; 42(11):1503-1510. PubMed ID: 30039885
[TBL] [Abstract][Full Text] [Related]
27. p53 Ubiquitination and proteasomal degradation.
Love IM; Shi D; Grossman SR
Methods Mol Biol; 2013; 962():63-73. PubMed ID: 23150437
[TBL] [Abstract][Full Text] [Related]
28. TRIM65 Promotes Cervical Cancer Through Selectively Degrading p53-Mediated Inhibition of Autophagy and Apoptosis.
Wang XY; Mao HW; Guan XH; Huang QM; Yu ZP; Wu J; Tan HL; Zhang F; Huang X; Deng KY; Xin HB
Front Oncol; 2022; 12():853935. PubMed ID: 35402260
[TBL] [Abstract][Full Text] [Related]
29. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.
Allende-Vega N; Saville MK
Semin Cancer Biol; 2010 Feb; 20(1):29-39. PubMed ID: 19897040
[TBL] [Abstract][Full Text] [Related]
30. TRIM65 Promotes Malignant Cell Behaviors in Triple-Negative Breast Cancer by Impairing the Stability of LATS1 Protein.
Lu Y; Xiao Y; Yang J; Su H; Zhang X; Su F; Tian B; Zhao D; Ling X; Zhang T
Oxid Med Cell Longev; 2022; 2022():4374978. PubMed ID: 36035221
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression.
Qin Y; Cui H; Zhang H
Technol Cancer Res Treat; 2016 Oct; 15(5):707-15. PubMed ID: 26113559
[TBL] [Abstract][Full Text] [Related]
32. TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.
Lv Y; Huo Y; Yu X; Liu R; Zhang S; Zheng X; Zhang X
Drug Des Devel Ther; 2016; 10():3053-3064. PubMed ID: 27729767
[TBL] [Abstract][Full Text] [Related]
33. WDR5 positively regulates p53 stability by inhibiting p53 ubiquitination.
Xie Q; Li Z; Chen J
Biochem Biophys Res Commun; 2017 May; 487(2):333-338. PubMed ID: 28412363
[TBL] [Abstract][Full Text] [Related]
34. TRIM65 Promotes Invasion of Endometrial Stromal Cells by Activating ERK1/2/C-myc Signaling via Ubiquitination of DUSP6.
Wu YT; Ma SY; Sun WQ; Shen WW; Zhu HT; Zhang Q; Chen HF
J Clin Endocrinol Metab; 2021 Jan; 106(2):526-538. PubMed ID: 33146694
[TBL] [Abstract][Full Text] [Related]
35. RING finger protein 31 promotes p53 degradation in breast cancer cells.
Zhu J; Zhao C; Zhuang T; Jonsson P; Sinha I; Williams C; Strömblad S; Dahlman-Wright K
Oncogene; 2016 Apr; 35(15):1955-64. PubMed ID: 26148235
[TBL] [Abstract][Full Text] [Related]
36. Trim65: a cofactor for regulation of the microRNA pathway.
Li S; Wang L; Fu B; Dorf ME
RNA Biol; 2014; 11(9):1113-21. PubMed ID: 25483047
[TBL] [Abstract][Full Text] [Related]
37. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
Cai Y; Yan X; Zhang G; Zhao W; Jiao S
Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
[TBL] [Abstract][Full Text] [Related]
38. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
Daks AA; Melino D; Barlev NA
Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
[TBL] [Abstract][Full Text] [Related]
39. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
40. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
